Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. develops and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. Company news centers on its advanced ceramics platform, FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, OsseoSculpt™ biologic, and SiNERGY™ silicon nitride/PEEK composite materials for patient-specific implant applications.
Recurring updates also cover commercialization milestones, first-in-human use of SINTX implants, strategic supply and private-label agreements, patent activity in antipathogenic materials, capital actions, operating efficiencies, and management or board changes. The company’s updates frame its current focus around medical-device applications, orthopedic and spine markets, U.S.-based manufacturing, and partnerships that extend the use of silicon nitride biomaterials.
SINTX Technologies and Oxford Performance Materials have developed a new orthopedic coating using PEKK and silicon nitride. This composite technology aims to address risks associated with metallic implants, such as infection and metal ion exposure. The coating enhances bone integration and resists bacterial adhesion, presenting an innovative solution for implants in orthopedics and dentistry. While the technology is FDA approved for individual components, further testing is underway to secure regulatory approval for the composite coating. Initial industry feedback has been positive, suggesting wide application potential.
SINTX Technologies announced the acquisition of Technology Assessment and Transfer, Inc. (TA&T), enhancing its capabilities in the aerospace, defense, and biomedical markets. This strategic move is expected to generate immediate revenue for SINTX through TA&T’s existing relationships with commercial partners and the U.S. government. TA&T specializes in advanced ceramics, including 3D printing for medical devices and innovative materials for industrial applications. The acquisition aims to leverage synergies between the two companies to further their growth and success.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the filing of its 2021 Annual Report on Form 10-K with the SEC. The company has made significant investments in 2021 to expand its biomedical, industrial/armor, and antipathogenic business segments, focusing on revenue-generating opportunities, including armor materials and biomedical implants. A conference call is scheduled for April 13, 2022, to update stakeholders. SINTX manufactures advanced ceramics at its facilities in Salt Lake City, Utah, and is dedicated to developing advanced material-based solutions.
SINTX Technologies announced a $300k Phase 1 grant from the National Institutes of Health to develop 3D printed silicon nitride and polyetherketoneketone implants for craniomaxillofacial surgery. This collaboration with Drexel University and others aims to enhance implant performance by reducing failure rates linked to infections and poor integration. Over 235,000 CMF surgeries occur annually in the U.S. with a 5.5% failure rate. The grant supports the commercialization of this innovative material that could significantly improve patient outcomes.
SINTX Technologies, Inc. (NASDAQ: SINT) announced advancements in manufacturing technologies for fabrics impregnated with silicon nitride, highlighting successful antipathogenic testing results. Recent tests showed that the embedded fabric effectively inactivated Staphylococcus Aureus and SARS-CoV-2, indicating enhanced antiviral properties. These developments reinforce SINTX's collaboration with a private European firm and mark significant milestones in the production of antipathogenic fabrics for various applications, including medical gowns and facemasks.
SINTX Technologies, Inc. (NASDAQ: SINT) announces the retirement of Chief Scientific Officer Dr. Bryan J. McEntire after 17 years. Dr. Ryan Bock, currently Director of R&D, will step in as Vice President of R&D, leading ongoing biomaterial development and expanding research on antipathogenic ceramics. Dr. McEntire has made significant contributions to the company, including research and product development for orthopedic implants made from silicon nitride. He will remain connected to SINTX in an advisory role.
SINTX Technologies recently provided a year-end business update, highlighting advancements in its biomedical, antipathogenic, and industrial segments. The company initiated joint research with leading universities under an NIH grant to develop 3D-printed silicon nitride PEEK composite spinal implants. New patent protections for antipathogenic applications offer potential commercial opportunities. Additionally, SINTX is constructing updates to its manufacturing facility for full production. Notably, the company received full forgiveness of a $509,148 SBA PPP loan, strengthening its financial position.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the launch of its subsidiary SINTX Armor, signing a 10-year lease for a facility in Salt Lake City for development and manufacturing. The facility will house equipment moved from Dayton, OH, with construction updates underway to facilitate machine qualification starting December 2021. The new facility will produce advanced ceramic armor, including BoroShock and DuraShock, aimed at military and industrial applications. Revenue growth is anticipated in H2 2022 as production begins.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the termination of its Patent License Agreement with O2TODAY due to delays in product development.
This follows SINTX's previous evaluation of joint efforts with O2TODAY, emphasizing its commitment to developing antiviral and antimicrobial fabrics using SINTX's patented FleX SN-AP silicon nitride powder. SINTX continues to pursue collaborations and product development in the antipathogenic fabric space, vital to its business strategy.
SINTX Technologies reported preliminary Q3 2021 revenue of approximately $240k, surpassing Q1 and Q2 revenues. Revenue stems from three sectors: spinal implants, antipathogenic fabrics, and armor. The company anticipates new revenue in Q4 2021 from open prototype orders for aerospace components and industrial applications. SINTX is focused on expanding its presence in advanced ceramics manufacturing at its FDA and ISO certified facility. A detailed business update will follow the upcoming Quarterly Report on Form 10-Q.